Evidence & regulatory context
- Mechanism
- c-Jun N-terminal kinase 3 inhibitor
- Target
- c-Jun N-terminal kinase 3
- Injury models
- TBI
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- In trials, not approved
- ChEMBL max phase
- 3 / 4 (development scale, not regulatory approval)
- Synonyms
- Brimapitida; Brimapitide; Xg-102; D-JNKi1; AM-111; D-jnki-1
- Note
- Not recorded
Clinical trials 6
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
A Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Phase III Study of the Efficacy and Safety of a Single Sub-conjunctival Injection of XG-102 for the Reduction of Post-cataract Surgery Intraocular Inflammation
Inflammation · Pain · Cataract
Enrolment: 339 · Results not recorded
Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss
Hearing Loss
Enrolment: 256 · Results not recorded
A Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Phase III Study of the Efficacy and Safety of a Single Sub-conjunctival Injection of XG-102 for the Reduction of Post-cataract Surgery Intraocular Inflammation
Inflammation · Pain · Cataract
Enrolment: 309 · Results not recorded
Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment
Hearing Loss, Idiopathic Sudden Sensorineural
Enrolment: 56 · Results not recorded
Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalation Phase II Study
Hearing Loss
Enrolment: 210 · Results not recorded
The Safety, Tolerability and Pharmacokinetics of a Single Intravenous Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Male Volunteers in a Randomized, Double Blind, Placebo Controlled, Dose Escalating Phase I Study
Inflammation
Enrolment: 24 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseTBIControlled cortical impact3xTg-AD (PS1M146V knockin, APPswe and TauP301L)both sexesn = 9 D-JNKi1-treated and 8 D-TAT-treated mice, under an option…intracerebroventricular injection into the right lateral ventricle, infused at 0.3 microlitres/min5 micrograms in 5 microlitres of PBS with 0.1% DMSOimmediately after controlled cortical impact
Model: controlled cortical impact traumatic brain injury through a 5 mm craniotomy, 3.0 mm tip centred 3.0 mm anterior to lambda and 2.7 mm left of midline, impact 2.0 mm below the dura
D-JNKi1 reduced phospho-c-jun immunoreactivity by about 40% and axonal accumulation of total tau, pS199 tau and PHF1 tau, but did not change APP-positive axonal varicosities or pT231 tau.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.
